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Abstract 
 
The present pathological study on the male rats aims to investigate the effects on liver tissue induced by repeated 
administration of three doses of sustanon for four periods. The experiment was done on the 100 adult male rats randomly 
divided into five groups 20 rats in each group. The first group is considered as a negative control treated with diet and water 
only. The second group is considered a positive control treated weekly for 60 days with sesame oil intramuscularly while 
groups III, IV and V treated with diluted sustanon in 5, 10 and 20 mg/kg body weight intramuscularly weekly for 60 days 
respectively. Blood was collected in a period 15, 30 and 60 days after treatment for measurements liver function tests ALT 
(alanine aminotransferase) and AST (aspartate aminotransferas) enzymes. Then the animals were dissected to take samples in a 
period 15, 30 and 60 days after treatment for histopathological examination, then 5 rats were lefted in each group in the diet 
and water for 30 days after last treatment for examination the above mentioned parameters. The results revealed the presence 
of significantly increasing of liver enzyme activation represented by ALT and AST at level P<0.05 compared with control 
groups. The value of these levels were higher in group V in a day 60 after treatment and its continue to increase even after 
stopping treatment and remained on diet and water only for 30 days. Pathologically, all treated groups with sustanon revealed 
gross and histopathological changes in liver tissue, there were enlargement and congestion gross. Histopathologically, the liver 
sections elucidate cellular swelling, vacuolar degeneration in the cytoplasm of hepatocytes in addition to fatty change and 
programmed cell death in all groups during a period 15, 30 and 60 days these changes continue even after stopping the 
treatment for 30 days but portal fibrosis has been observed.It has been concluded from this study that sustanon in 
concentration 5, 10, 20 mg /kg of body weight in aperiods 15, 30 and 60 have ability to induce hepatotoxic effect on liver of 
male rat and these effects irreversible and progressive for 30 days after stopping the drug administration. 
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نوناتسسلا) يئانبلا ديوريتسلل ةيضرملا تاريثاتلا ( ناذرجلا روكذ دبك ىلع   
  
ينانكلا ميحر راصتنا    و ينادمحلا لعزخ راصتنا   
  
جاودلا ضارماو ضارملاا عرف ن  ، يرطيبلا بطلا ةيلك  ، لصوملا ةعماج لا ، لصوم  ، قارعلا   
  
ةصلاخلا   
  
ةمدقملا ةساردلا نا   ىلا فدھت   ةيضرملا تاريثاتلا نع فشكلا   يف    ةعبرا ىلعو نوناتسسلا نم عرج ةثلاث ءاطعاب ثدحملاو دبكلا جيسن
ةيلاتتم تارتف .    ناذرجلا روكذ ىلع ةبرجتلا تيرجا , ايئاوشع تمسق   ع عيماجم ةسمخ ىلا ةعومجم لكل اذرج نورش .  ىلولأا ةعومجملا
 ةبلاس ةرطيس ةعومجم تدع فلعلاو ءاملاب اھتلماعم مت  ،  مسمسلا تيزب اھنقح مت ةبجوم ةرطيس ةعومجم  ْتّدُع دقف ةيناثلا ةعومجملا
 ةدمل ًايعوبسأ ٦٠    ،لضعلاب نقحلا قيرط نع اموي امنيب   ھتلماعم مت دقف ةسماخلاو ةعبارلاو ةثلاثلا عيماجملا  ا  ففخملا نوناتسسلا بكرمب
لابو زيكارت   ٥   و ١٠   و ٢٠    ةدملو ًايعوبسأ يلاوتلا ىلع مسجلا نزو نم مغك /مغلم ٦٠   ،يلضعلا نقحلا قيرط نع اموي   مدلا بحس ّمت    للاخ
 تارتفلا ١٥ و ٣٠ و ٦٠    ضرغل ةلماعملا دعب اموي  دبكلا فئاظو تاميزنا سايق  تيترابسلاا نيمأ لقانب ةلثمتملا Aspartate aminotransferase 
enzyme (AST)    نينللاا نيمأ لقانو Alanine aminotransferase enzyme (ALT)    مت اھدعب  نم جذامن ذخاو تاناويحلا حيرشت  عقاوب دبكلاIraqi Journal of Veterinary Sciences, Vol. 28, No. 1, 2014 (31-39) 
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تانيع ةسمخ    ةعومجم لك نم ارتفلا دنعو ت   هلاعا ةروكذملا .   تكرت    سمخ  ةدمل فلعلاو ءاملا ىلع ةعومجم لك نم ناذرج ٣٠    دعب ًاموي
ةلماعم رخأ   مت   لتقلا ءارجاو و مدلا بحس   ميحرلا   Euthanesia   دبكلا جذامن ذخاو تاناويحلل    دبكلا فئاظو تاميزنا سايق نا لھ ةفرعمل
ةيعجر ما ةيمدقت ةيضرملا تاريغتلاو .   ةيلاعف نم لك ىوتسم يف يونعم عافترا دوجو جئاتنلا تنيب    لقانب ةلثمتملا دبكلا فئاظو تاميزنإ
 تيترابسلاا نيمأ Aspartate aminotransferase enzyme (AST)    نينللاا نيمأ لقانو Alanine aminotransferase enzyme (ALT)  تناكو .
 مويلا يف ةسماخلا ةعومجملا دنع ةدش رثكأ تايوتسملا هذھ ميق ٦٠    ةيونعم ىوتسم دنعو ةلماعملا دعب P<0.05    ةرطيسلا يتعومجمب ةنراقم
 عافترلااب ترمتساو (ةيناثلاو ىلولأا)  تاناويحلا كرت دعب ىتح ٣٠   أ دعب ًاموي .طقف فلعلاو ءاملا ىلع ةلماعم رخ    ةيضرملا ةيحانلا نم اماو
عيماجملا ةفاك ترھظأ دقف   يف ةيجسنو ةينايع ةيضرم تاريغت نوناتسسلاب ةلماعملا   دبكلا جيسن    ًامخضت ًاينايع جئاتنلا تحضوأ ثيح
طاقملا ترھظأ ًايجسن ،دبكلا يف نيديدش ًاناقتحاو  تاريغتلا نع ًلاضف يوجفلا سكنتلاو يولخلا مروتلاب تلثمت تاريغت دوجو ةيجسنلا ع
 تارتفلا دنعو عرجلا ةفاك يفو جمربملا يولخلا توملا نع ًلاضف ةيدبكلا ايلاخلا يلويھ يف ةينھدلا ١٥   و ٣٠   و ٦٠    ةلماعملا دعب ًاموي
ت دعب ةيبابلا ةحابلا يف فيلتلا اھبحاصو تاريغتلا هذھ ترمتساو  ةدمل تاناويحلا كر ٣٠     ًاموي   رخأ دعب فلعلاو ءاملا ىلع ةلماعم .    نم جتنتسن
 عرجلا دنعو نوناتسسلل ناب ةساردلا هذھ ٥   و ١٠   و ٢٠    تارتفلا للاخو مسجلا نزو نم مغك /مغلم ١٥   و ٣٠   و ٦٠    رشابم ريثات هل تناك ًاموي
 ةدمل تلاماعملا عاطقنا دعب ىتح ترمتساو ناذرجلا روكذ دبك ىلع ٣٠   اموي    ىوتسم ىلع تاريغت اھقفارت طقف فلعلاو ءاملا ىلع اھتيذغتو
.ةيمدقت تاريغتلا هذھ تناكو دبكلا فئاظو  
 
 
Introduction 
 
The phenomenon of abusing Anabolic androgenic 
steroids (AAS) by many youth and athletes is aserious 
health phenomenon which increase rapidly in recent years 
(1,2). Anabolic androgenic steroids are group of synthetic 
compounds related to testosterone structurally (3,4) 
androgens play a central role in the biology on medical 
practice in status as muscle wasting or debilitation (3). The 
high doses of these anabolic steroids such as 
metanedienone, stanozolole,oxandrolone and sustanon, in 
order to abtain and produce arapid and huge increasing in 
the skeletal muscle mass and to improve there performance 
during the sport competition (5). 
For instance,sustanon (Androgenicum prolongatum) is 
one of these AAS which has many useful therapeuties 
usages, it is clinically used to treat cases of osteoporosis, 
male hypogonadisms and infertility (6). Inregard sustanon it 
is characterized by avery unique and distinguish 
pharmacological structure and properties comparing to 
other AAS drugs,it is consiste of an oily mixture of four 
different testosterone ester compound which provide a 
continuous release of testosterone into the blood serum for 
duration extent to 3 – 4 weeks (7,8).  
These drugs was giving to race horse and dogs who 
wish to improve physical performance (1,8,9). Anabolic 
androgenic steroids suggest could be apossible new risk 
facter for causing adisease termed toxicant associated 
steatohepatitis (TASH) (10). It have ability to give 
significant increase in muscle mass and strength, these are 
the main reasons why many body builders prefer to include 
sustanon dosage in the cycle because it can produce 
immediate results as a fast acting steroid,Beside this 
significant, there was many side effect produce from using 
sustanon.for example since that compound easily converted 
to estrogen so increase growth of breast tissues, this 
condition called gynecomastia (11).  
Previous studies also reported many serious adverse 
effects resulted from abusing these anabolic drugs which 
induce cardiovascular disorder (particularly enlargement of 
the left ventricle) which can lead to sudden death, acute 
hepatitis and jaundice, testicular dysfunction, which lead to 
infertility, hypertension, behavioral disorders (12-20). 
By reviewing the literature it was observed that hepatic 
histological changes induced by sustanon have been limited 
studies so, this study conducted to documented and reported 
the histological and biochemical alteration in liver enzymes 
of graded doses of sustanon in different peroids on hepatic 
tissue.  
 
Materials and methods 
 
Ethical approval 
The study was approved by Section of Animal Ethics 
Committee in the College of Veterinary Medicine, 
University of Mosul. 
Male albino rats were obtained as three months old from 
laboratory animal house of veterinary medical college, 
body weight 250-350 gm. Animals had free access to 
laboratory chaow and tap water. They were maintained on a 
12:12 hour light – dark cycle and housed in an animal room 
where the temperature (22-26°C) was controlled. 
100 male rats were randomly divided into 5 groups of 
20 rats each. Group I received the regular rate diet and 
maintained as negative control group, group II were 
intramuscular (IM) injected with sesame oil (Which used to 
dilute sustanon for injection), group III, IV, and V treated 
with IM injection of sustanon (Androgenicum prolongatum) 
in concenteration 250mg/ml (obtained from organon Oss 
Holand company)  about (5, 10 and 20 mg/kg of body 
weight), respectively for 60 days one dose weekly.five rats Iraqi Journal of Veterinary Sciences, Vol. 28, No. 1, 2014 (31-39) 
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from each group remained for 30 days (30 days after 
stopping of treatment additives on normal diet and water 
only). 
Blood samples were taken from eye vein, after over 
neight fast for 12 hours and biochemical analysis performed 
in fresh heparin treated serum. 
Serum were collect at 15, 30 and 60 days after treatment 
then at 30 days after stopping the administration of 
sustanon and only dieting on normal diet and water. Serum 
was obtained by centrifugation at 3000 RPM for 15 minutes 
and stored at -4°C for enzyme assays. 
ALT, AST were analyzed by using commercial kits 
from Biolabo French Company. 
Sustanon obtained from organon Oss Holand company 
(250 mg/ml) and the volume used is 5 ml. and we use 
sesame oil from Bailasan company/mosul/Iraq.  
 
Procedures 
For light microscopy livers of the animal from different 
groups were examined for gross fixed then perfused in 10% 
neutral buffered formaline for 48-72 hours. The specimens 
were dehydrated in ascending grades of alcohol, clearing in 
xylene and embedded in paraffin wax, 4-6 Microne 
thickness sections were obtained and stained with Harris 
haematoxylin and eosin (H&E) for microscopic 
examination (21). 
 
Statistical Analysis 
We use SPSS program Sixteen edition we use analysis 
of Varians ANOVA (one way analysis) and Duncan's test to 
test the significant differences between the groups at level 
P<0.05 (22). 
 
Results 
 
Results of the blood serum biochemical analysis are 
listed in table 1 and 2, a significant difference in the level of 
ALT enzyme in the blood serum of male rats treated with 
sustanon in a dose 5, 10, 20 mg/kg body weight compare 
with control groups in a periods 15, 30 and 60 days after 
treatment at level P<0.05 was observed, and the highly 
value are recorded in GV (20 mg/kg) reach 56.82 ± 1.29 
IU/L (table 1). 
The percentage level of ALT enzyme in all treated 
groups with sustanon  in a dose 5, 10, 20 mg/kg B.W. 
revealed increased in all group treated but the highest 
percentage showed in group V which reach 32%, 34% and 
34% in a periods 15, 30 and 60 days respectively (Figures 
1). 
While table 2 revealed a significantly increasing and 
difference in a level of AST enzyme in blood serum of male 
rats treated with sustanon at a dose 5, 10, 20 mg/kg/BW at 
level P<0.05 in a period 15, 30 and 60 days after treatment, 
also the highly values were recorded in GV (20 mg/kg) 
B.W. at a day 60 which reach 69.50 ± 1.40 IU/L, and the 
percentage of level of AST enzyme in all treated groups of 
A. p.illustrated a significantly increased in their percentage 
and the highly percentage was recorded in group V which 
reach 32%, 35% and 36% via the periods 15, 30 and 60 
days respectively (Figures 2). 
 
Table 1: Level of ALT enzyme IU/L in the blood serum of male rats treated with sustanon in a dose (5, 10, 20) mg/kg B.W. 
compare with control groups (G1 and G2) 
 
Groups Treatments  Value / Days 
Day 15  Day 30  Day 60 
Group 1 
I 
Negative control 
(Food &Water) 
10.75±0.70
C a
10.66±0.56 
D a
11.53±0.39
D a
Group 2 
II 
Positive Control Treated 
with sesame oil 
10.00±0.96
C a
10.54±0.80 
D a
10.46±0.65
D a
Group 3 
III 
Treated with sustanon in 
dose 5 mg/kg 
34.11±2.27
B b
35.68±2.37 
C ab
40.30±0.72
C a 
Group 4 
IV 
Treated with sustanon in 
dose 10 mg/kg 
37.77±1.54
B b
46.78±1.72 
B a
46.46±1.47
B a
Group 5 
V 
Treated with sustanon in 
dose 20 mg/kg 
42.74±0.78
A b
54.68±1.28 
A a
56.82±1.29
A a 
The value expressed by Mean ± Standard Error, Capital litter which are different vertically means there are significant 
difference between groups at level P<0.05. Small litter which are different horizontally means there are significant difference 
within the groups at level P<0.05. N= 5. 
  
The table 3 revealed a significantly difference in a level 
of ALT enzyme in blood serum of male rats treated with 
sustanon in dose (5, 10 and 20) mg/kg body weight after 30 
days from discontinuation of treatment at level P<0.05 
compare with control groups (20 mg/kg B.W.) compare 
with 60 days after treatment. On other hand table 3 reveals Iraqi Journal of Veterinary Sciences, Vol. 28, No. 1, 2014 (31-39) 
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a significant increases and differences in a level of AST in 
blood serum of male rats treated with sustanon in dose 5, 
10, 20 mg/kg B.W. after 30 days discontinuation 
oftreatment with A. p.at level P<0.05 as compared with 
control groups (GI and GII) while highly value recorded in 
group V (20 mg/kg B.W.) as compared with its level at a 
day 60. 
 
Table 2: Level of AST enzyme IU/L in the blood serum of male rats treated with sustanon in dose (5, 10, 20) mg/kg B.W. 
compare with control groups (G1 and G2) 
 
Groups Treatments  Value / Days 
Day 15  Day 30  Day 60 
Group 1 
I 
Negative control 
(Food &Water) 
10.40±0.80
B a 
10.80±0.79 
D a
10.66±0.56
E a
Group 2 
II 
Positive Control Treated 
with sesame oil 
37.44±3.80
AB b
13.23±0.78 
D a
13.96±0.21
D a
Group 3 
III 
Treated with sustanon in 
dose 5 mg/kg 
37.45±1.49
AB b
40.58±0.89 
C ab
43.54±0.83
C a 
Group 4 
IV 
Treated with sustanon in 
dose 10 mg/kg 
44.10±1.76 
AB b
52.21±1.69 
B a
54.15±0.87
B a
Group 5 
V 
Treated with sustanon in 
dose 20 mg/kg 
51.08±2.36
A c
63.54±1.26 
A b
69.50±1.40
A a 
The value expressed by Mean ± Standard Error. Capital litter which are different vertically means there are significant 
difference between groups at level P<0.05. Small litter which are different horizontally means there are significant difference 
within the groups at level P<0.05. N = 5.  
 
Table 3: Level of ALT and AST enzyme IU/L in the blood serum of male rats treated with sustanon in concentration (5, 10, 
20) mg/kg B.W. compare with control groups (G1 and G2) 
 
Groups Treatments 
Value / Days 
ALT AST 
Day 60  Day 30 after last 
treatment  Day 60  Day 30 after last 
treatment 
Group 1 
I 
Negative control 
(Food &Water) 
11.53±0.39
D a
11.93±0.57 
A a 
10.66±0.56 
E a 
10.88 ± 0.82 
D a 
Group 2 
II 
Positive Control 
Treated with sesame oil 
10.46±0.65
D a
10.48±0.95
A a 
13.96±0.21 
D a 
12.19 ± 0.58
D a 
Group 3 
III 
Treated with sustanon 
in dose 5 mg/kg 
40.30±0.72
C b 
47.79±2.32
B a 
43.54±0.83 
C a 
52.00 ± 3.11
C a 
Group 4 
IV 
Treated with sustanon 
in dose 10 mg/kg 
46.46±1.47 
B b
56.75±1.33
C a 
54.15±0.87 
B b 
64.88 ± 1.52 
B a 
Group 5 
V 
Treated with sustanon 
in dose 20 mg/kg 
56.82±1.29 
Aa
61.58±1.97
Da
69.50±1.40 
A a 
73.52 ± 1.15 
Aa
The value expressed by Mean ± Standard Error. Capital litter which are different vertically means there are significant 
difference between groups at level P<0.05. Small litter which are different horizontally means there are significant difference 
within the groups at level P<0.05. N = 5. 
 
Pathological changes 
Macroscopic Changes 
Rats liver treated with 5 mg/kg/B.W. of sustanon 
showed swelling association with pin point hemorrhage in a 
period 15, 30 and 60 days of IM injection. This lesion 
continue and more evidence at 30 days after stopping 
treatment as compared with control group moreover in a 
dose 20 mg/kg B.wt. Severe enlargement with fatty in 
consistency associated with petechial hemorrhage on 
ventral surface of hepatic tissue was observed (Figure 3), at 
15 and 30 days and more evidence at 60 days post treated, 
but after leaving animal without treatment with sustanon for 
30 days it showed granules in consistency associated with 
sever congestion (Figure 4), as compared with control 
groups.  Iraqi Journal of Veterinary Sciences, Vol. 28, No. 1, 2014 (31-39) 
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Figure 1: Percentage of ALT in serum of male rats of all 
groups treated with sustanon at day 15 (A), 30 (B) and 60 
(C) as compared with control groups. 
 
 
 
Figure 2: Percentage of AST in serum of male rats of all 
groups treated with sustanon at day 15 (A), 30 (B) and 60 
(C) as compared with control groups. 
 
Microscopic changes 
Histopathological section of rats liver showed no 
histological lesions in control groups, while in group treated 
with sustanon in a dose 5 mg/kg Bwt after 15 days 
illustrated congestion of blood vessels (artery and vein) in 
portal area, sinusoidal congestion and dilation in addition to 
privascular of mononuclear inflammatory cells. Vacuolar 
degeneration and cell swelling, also observed. Some 
sections revealed fatty change hypertrophied kupffer cells 
and pyknotic nuclei of hepatocytes (Figuer 5). At 30 days 
all lesions observed at 15 days continous, in addition to 
programmed cell death of some hepatocytes (Figuer 6). 
 
      
 
Figure 3: Rats liver treated with sustanon in a dose 10 
mg/kg Bwt in a day 30 showed enlargement and sever 
congestion (A) and pinpoint hemorrhage (arrows).  
 
      
 
Figure 4: Rats liver treated with 20 mg/kg Bwt in a day 15 
showed sever palness (arrow) with fatty consistency and 
pin point hemorrhage (A). 
 
A  B 
C 
G I 
G II 
G III 
G IV 
G V 
  
 
A  B 
C 
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Figure 5: Histological section of rat liver treated with 
sustanon in a dose 5 mg/kg of body weight after 15 days 
showed sever congestion of central vein and sinosoids (A) 
vacuolar degeneration in the cytoplasm of hepatocytes (B). 
Stain: H&E, 560X. 
 
       
 
Figure 6: Histological section of rat liver treated with 
sustanon in a dose 5 mg/kg of body weight after 30 days 
showed sever congestion in sinosoids (A) vacuolar 
degeneration (B), swelling of kuffer cell  (arrow). Stain: 
H&E, 560X. 
 
While at 60 days sections of liver revealed loss the 
normal architectures of lobules in addition to congestion of 
blood vessels and programmed cell death of hepatocytes. 
Rat treated with 10 mg/kg Bwt at 15 days also showed 
same changes but more sever. At 30 – 60 days figures 
showed sever congestion of blood vessels and diffuse 
vacuolar degeneration in addition to congestion necrosis, 
and infiltration of mononuclear inflammatory cells with 
programmed cell death (Figuer 7).  
 
       
 
Figure 7: Histological section of rat liver treated with 
sustanon in a dose 10 mg/kg of body weight after 60 days 
showed sever vacuolar degen eration (A) and foci of 
coagulation necrosis (B) programmed cell death (arrow). 
Stain: H&E, 560X. 
 
        
  
Figure 8: Histological section of rat liver treated with 
sustanon in a dose 20 mg/kg of body weight after 15 days 
showed loss of normal arrangement of hepatic cords and 
sever vacuolar degeneration in the cytoplasm of 
hepatocytes (A) congestion of sinosiod (arrow). Stain: 
H&E, 450X. 
A
A 
B 
 
A 
A 
B 
B 
A  
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Rats administrated with 20 mg/kg b.wt. in a day 15 
showed lobular and centrolobular necrosis, hypertrophy and 
hyperplasia of kupffer cells, while at 30 – 60 days, all 
lesions continue in addition to hyperplasia of epithelial 
lining bile duct (Figure 8).  
 
       
 
Figure 9: Histological section of rat liver treated with 
sustanon in a dose 10 mg/kg of body weight after 30 days 
of stopping of treatment, Showed dilatation of sinosoids (A) 
with programmed cell death of hepatocytes (arrows). Stain: 
H&E, 450X. 
   
      
 
Figure 10: Histological section of rat liver treated with 
sustanon in a dose 20 mg/kg of body weight after 30 days 
of stopping of treatment, showed sever fibrosis in portal of 
area (A) with congestion of blood vessels (B) and 
proliferation of bile lacnni (arrows). Stain: H&E,200X. 
 
In animal left without treatment with A. p. for 30 days 
and feeding on normal diet and water only liver showed 
portal fibrosis (collagen proliferation, newly capillaries and 
newly caniliculi), bile pigment deposition in addition to loss 
of the normal arrangement of hepatic cord and appoptic 
hepatocytes (Figuers 9-11). 
 
       
  
Figure 11: Histological section of rat liver treated with 
sustanon in a dose 20 mg/kg of body weight after 30 days 
of stopping of treatment, show programmed cell death of 
hepatocytes (arrows). Stain: H&E, 450X. 
 
Discussion   
 
The result of this study showed that IM injection of 
sustanon at 5, 10, 20 mg/Kg BW for 15, 30 and 60 days 
induce hepatotoxicity in male rats of groups III, IV and V 
as verified by biochemical and histological finding, and 
marked elevation in level of ALT and AST in blood serum 
of male in group III, IV, V as compared with control groups 
and these elevation continued after stopping treatment for 
30 days, suggestion that these changes reflected the 
occurrence of liver injury. The present results support the 
previous study of (23) who reported that administration of 
sustanon  in a dose 5 mg/kg b.w. subcutaneously for 10 
weeks cause increase level of ALT as compared with 
control group. The elevation of ALT and AST in blood 
serum with increasing the dose means damages of 
hepatocytes was take place through the damaging of 
mitochondria, which lead to leakage this enzyme outside of 
hepatocytes and reach to blood ALT is more specific for 
liver injury than AST (24). Using anabolic steroid randomly 
for long time can induce hepatotoxicity and morphological 
alterations of the liver cells.  
A 
A 
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On the other hand, AST activity was increased in animal 
treated with sustanon, it may indicate the presence of 
muscle damage as well as hepatocytes because these 
enzyme is specific for muscle so it means that damage of 
muscle also take place (25). 
This study was not in agreement with other studies 
shows that serum parameters commonly evaluated in 
athletes to test hepatic function are not substantially 
modified by administration of the anabolic steroids 
employed (26). The uses of anabolic androgenic steroids 
particularly sustanon cause alteration in liver function due 
to alteration in morphological and histological structure of 
hepatocytes. The pathological changes revealed 
hypertrophy, congestion in central vein and sinusoid 
(particularly in 20 mg/kg Bwt for 30 to 60 days) indication 
for chronic venous congestion takeplace, also fatty changes 
in consistency was observed, and these changes reflect to 
injury of liver cell occurrence due to toxic hypoxia 
producing from different doses of sustanon  like other 
anabolic steroid (16). Congestion and hemorrhage take 
place due to increase hydrostatic pressure in blood cause 
vessels accumulation of red blood cell in the lumen of 
blood vessels, which allow blood cells to diapedsis and 
leakage out the blood vessels to cause bleeding. Moreover, 
sustanon may have ability to cause lipid peroxidation via 
reactive oxygen species which lead to fatty changes in 
addition to hypoxia. 
Histopathological lesions also observed in this study 
started in 5 mg/kg Bwt, and reach to 20 mg/kg B.wt. in 15, 
30, 60 days which continues after stopping treatment for 30 
days, this means that sustanon  have ability to induce 
progress liver cell injury because its considered as a first 
organ responsible for metabolism of sustanon compound. 
So, this injury induced by accumulation of toxic metabolite 
(Xenobiotic) from sustanon metabolism that includes 17, α-
19-Nortesterone, 17-α-testosterone (27). 
On the other hand, figures showed cell swelling, 
sinusoid dilation and congestion in addition to centrolobular 
necrosis, these lesions occurs due to that sustanon like other 
anabolic androgenic steroid have ability to cause injury of 
hepatocytes through the effect on mitochondria particularly 
mitochondrial membrane and inhibit mitochondrial 
respiration which lead to swelling of mitochondria and 
cause leakage of ALT and AST (28). 
An interesting finding in this study was a presence of 
programmed cell death in hepatocytes, like other anabolic 
androgenic steroid for example blodenone undecyleante 
(29) they illustrated that this drug have ability to cause 
programmed cell death by using immunohistochemistry 
through increasing in a protein P53 which responsible for 
programmed cell death (so this observation need more 
studying in future). Also, our study suggested that sustanon 
have ability to cause programmed cell death through the 
ability to damage cell DNA and mitochondria.  
Moreover, this study showed presence of fibrosis in 
portal area particularly in animal lefted for 30 days after 
stopping the treatment, this means that liver go to healing 
the damaged cells by fibrosis in portal area not regeneration 
of other hepatocytes because the damage is powerful and 
strong and may need more than 30 days for regenerations 
because sustanon  remain in tissue for 4 weeks after 
stopping administration (29). 
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